NCT04505826 2025-08-24A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerOlema Pharmaceuticals, Inc.Phase 1/2 Completed153 enrolled